-
30 September, 2024
Regor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer
+Read More+ -
5 June, 2024
Regor to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
+Read More+ -
8 March, 2024
Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity
+Read More+ -
7 December, 2023
Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy
+Read More+ -
03 November, 2022
Regor announces China NMPA approval of the IND for RGT-264 phosphate tablet, a potent and selective HPK1 inhibitor
+Read More+ -
20 April, 2022
Regor announces China NMPA approval of the IND for RGT-419B capsule, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer
+Read More+ -
8 April, 2022
Regor announces the first patient dosed in the U.S. in the Phase I clinical trial for RGT-419B, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer
+Read More+ -
10 Dec, 2021
Regor and Lilly Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
+Read More+ -
18 Feb, 2021
Regor Therapeutics Announces Completion of $90 Million Series B Financing
+Read More+
About Us
Regor Therapeutics Group is a clinical-stage biotechnology company developing innovative and clinically differentiated medicines, with an in-house pipeline encompassing leading assets in oncology, metabolism and auto-immunity. By leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, Regor Therapeutics Group has completed 10+ PCCs inhouse, with 3 assets with clinical data, validating its highly efficient ecosystem for accelerated discovery of innovative therapeutic agents.
Our Pipeline
Regor has a portfolio of differentiated drug candidates focused on therapeutic areas with huge unmet needs: metabolism, oncology and auto-immunity.
Clinical pipeline of potential blockbusters:
1) RGT-075, a leading once-daily oral small molecule full agonist of GLP-1R;
2) RGT-419B, the only CDK4 inhibitor with single agent efficacy in refractory ER+/HER2- breast cancer.
Press Releases
245 Main Street, Second Floor, Cambridge, MA 02142, USA
